Semaglutide Cuts Heart Risk Beyond Weight Loss: Study

0 Views

Thanks! Share it with your friends!

You disliked this video. Thanks for the feedback!

Published Apr 21, 2025

A major study presented at the European Congress on Obesity reveals that semaglutide, a weight-loss drug found in Wegovy and Ozempic, lowers the risk of heart attacks, strokes, and cardiovascular death by 20%, even in those with mild obesity or minimal weight loss. Led by University College London, the trial involved over 17,000 participants and suggests semaglutide may offer heart-protective benefits beyond weight reduction, marking it as a potential breakthrough in cardiovascular treatment.

#wion #wionpodcast #scienceandtechnology

About Channel:

WION The World is One News examines global issues with in-depth analysis. We provide much more than the news of the day. Our aim is to empower people to explore their world. With our Global headquarters in New Delhi, we bring you news on the hour, by the hour. We deliver information that is not biased. We are journalists who are neutral to the core and non-partisan when it comes to world politics. People are tired of biased reportage and we stand for a globalized united world. So for us, the World is truly One.

Please keep discussions on this channel clean and respectful and refrain from using racist or sexist slurs and personal insults.

Subscribe to our channel at https://goo.gl/JfY3NI
Check out our website: http://www.wionews.com
Join our WhatsApp Channel: https://bit.ly/455YOQ0
Connect with us on our social media handles:
Facebook: https://www.facebook.com/WIONews
Twitter: https://twitter.com/WIONews
Instagram: https://www.instagram.com/wionews/
Follow us on Google News for the latest updates

Zee News:- https://bit.ly/2Ac5G60
Zee Business:- https://bit.ly/36vI2xa
DNA India:- https://bit.ly/2ZDuLRY
WION: https://bit.ly/3gnDb5J
Zee News Apps: https://bit.ly/ZeeNewsApps